Picket Pharmaceuticals Partners with Valisure to Enhance Drug Safety

Picket Pharmaceuticals Partners with Valisure for Drug Safety

Picket Pharmaceuticals has engaged with Valisure to significantly enhance transparency and independent validation of the chemical quality in the pharmaceutical supply chain. This cooperation marks a major step in addressing the pressing issues that have led to alarming drug shortages across the medical landscape.

Addressing Drug Shortages

The partnership aims to tackle the prevalent market failure surrounding generic drugs, often hindered by a lack of transparency and aggressive price competition. These factors have contributed to unprecedented drug shortages, which are now a serious public health challenge.

Public health is increasingly threatened by exceptional drug shortages, where quality problems are frequently cited as the cause. According to various data sources, a striking 76% of drug shortages stem from manufacturer quality issues that have persisted, even leading into recent years. Moreover, the alarming rate of recalls—approximately three per day in the U.S.—highlights the presence of dangerous impurities in the market.

The Importance of Quality Assurance

David Light, Co-Founder and President of Valisure, emphasized the need for independent testing and quality transparency. He noted, "Independent testing and transparency in the supply chain are essential for ensuring the safety and efficacy of medications. These components have been increasingly recognized as vital missing pieces in the generic drug market, contributing to continuous quality problems and shortages." This statement underscores the partnership's importance in improving drug quality standards.

Collaborative Efforts for Change

The alliance between Valisure and Picket Pharmaceuticals emerged from their shared involvement in the End Drug Shortages Alliance. At EDSA, the need to address the root causes of drug shortages led to proactive measures for reforming the pharmaceutical supply chain. Their collaboration is dedicated to establishing a model for quality and transparency across the industry.

Enhancing Transparency in Drug Supply

Both companies are committed to improving the quality assurance processes for injectable drugs, which face the most severe shortages. Joshua Kriger, Founder and CEO of Picket Pharmaceuticals, remarked, "We have admired Valisure's success in ensuring quality assurance for solid oral medications and felt it was crucial to extend this capability to injectable drugs, where challenges are substantial." Their partnership is set to reinforce Picket Pharmaceutical's commitment to delivering the highest quality standards.

Benefits to Stakeholders

This collaboration is expected to empower Picket Pharmaceuticals’ customers with significant insights into the chemical quality of their injectable products. By advocating for quality as a core element of sourcing and distributing medications, this initiative aims to tackle systemic challenges in the pharmaceutical industry.

About Valisure

Valisure stands at the forefront of solving significant gaps in the healthcare supply chain through their innovative quality assurance processes. Their mission is to reshape the landscape of healthcare supply by advocating for transparency and independent certification through rigorous chemical analysis. In a climate where reliability is critical, Valisure meets a substantial unmet need with their commitment to reforming the healthcare supply chain.

About Picket Pharmaceuticals

Picket Pharmaceuticals is tackling the ongoing issues of drug shortages and the associated risks within the supply chain for essential medicines. By employing various strategic models, they align existing stakeholders—including active ingredient suppliers, manufacturers, and healthcare providers—to enhance the flow of vital medications. Their goal is to elevate the quality of pharmaceutical offerings while minimizing unnecessary costs within the healthcare system.

Frequently Asked Questions

What is the main goal of the partnership between Picket Pharmaceuticals and Valisure?

The partnership aims to enhance transparency and quality assurance in the supply chain for injectable drugs, addressing ongoing issues related to drug shortages.

Why is independent testing important in the pharmaceutical industry?

Independent testing ensures the safety, quality, and efficacy of medications, helping to prevent market failures that can lead to drug shortages and recalls.

What percentage of drug shortages are caused by manufacturer quality issues?

According to recent data, approximately 76% of drug shortages are linked to manufacturer quality issues, highlighting a critical area for improvement.

How does Valisure contribute to improving drug quality?

Valisure provides independent chemical analysis and certification, fostering enhanced transparency and reliability in the pharmaceutical supply chain.

What is Picket Pharmaceuticals' approach to tackling drug shortages?

Picket Pharmaceuticals aims to align various stakeholders to optimize the supply chain for essential medicines, ensuring high-quality products reach patients effectively.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. If any of the material offered here is inaccurate, please contact us for corrections.